Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 14;8(1):18.
doi: 10.1186/s41181-023-00204-4.

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

Ashleigh Hull  1   2 , William Hsieh  3   4 , William Tieu  5 , Dylan Bartholomeusz  4   6 , Yanrui Li  3 , Eva Bezak  3   5
Affiliations

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer

Ashleigh Hull et al. EJNMMI Radiopharm Chem. .

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we characterised the in vitro behaviour of a novel beta-emitting radioimmunoconjugate [177Lu]Lu-DOTA-C595 as a therapeutic agent against PDAC. [177Lu]Lu-DOTA-C595 is designed to target cancer-specific mucin 1 epitopes (MUC1-CE) overexpressed on most epithelial cancers, including PDAC.

Results: A series of in vitro experiments were performed on PDAC cell lines (PANC-1, CAPAN-1, BxPC-3 and AsPC-1) exhibiting strong to weak MUC1-CE expression. [177Lu]Lu-DOTA-C595 bound to all cell lines relative to their expression of MUC1-CE. [177Lu]Lu-DOTA-C595 was also rapidly internalised across all cell lines, with a maximum of 75.4% of activity internalised within the PANC-1 cell line at 48 h. The expression of γH2AX foci and clonogenic survival of PANC-1 and AsPC-1 cell lines after exposure to [177Lu]Lu-DOTA-C595 were used to quantify the in vitro cytotoxicity of [177Lu]Lu-DOTA-C595. At 1 h post treatment, the expression of γH2AX foci exceeded 97% in both cell lines. The expression of γH2AX foci continued to increase in PANC-1 cells at 24 h, although expression reduced in AsPC-1. Clonogenic assays showed a high level of cell kill induced by [177Lu]Lu-DOTA-C595.

Conclusion: [177Lu]Lu-DOTA-C595 has favourable in vitro characteristics to target and treat MUC1-CE positive PDAC. Further investigations to characterise the in vivo effects and potential value of [177Lu]Lu-DOTA-C595 in other MUC1-CE expressing malignancies such as lung, ovarian and colorectal adenocarcinoma are warranted.

Keywords: C595; Lutetium-177; MUC1; Pancreatic cancer; Radioimmunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A Cell binding of [177Lu]Lu-DOTA-C595 at 1 × 105 cells corrected for background and B linear regression of the percentage of positive MUC1-CE cells and average cell binding counts per minute
Fig. 2
Fig. 2
Background- and decay-corrected cell counts across 48 h representing A surface binding, B internalised fraction, C total binding including surface and internalised and D rate of internalisation
Fig. 3
Fig. 3
Representative flow cytometry histograms of γH2AX expression in PANC-1 and AsPC-1 cells at A and B 1 h, and C and D 24 h following [177Lu]Lu-DOTA-C595 treatment
Fig. 4
Fig. 4
Clonogenic survival of A PANC-1 and AsPC-1 at varying concentrations of [177Lu]Lu-DOTA-C595, B PANC-1 and C AsPC-1 cell survival following exposure to equivalent concentrations of [177Lu]Lu-DOTA-C595, Lu-177, DOTA-C595 and C595 and D intra-observer reliability of manual counting determined using the intra-class correlation coefficient (ICC). Data are presented as mean ± standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001
See this image and copyright information in PMC

References

    1. Al-Ejeh F, Darby JM, Thierry B, Brown MP. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution. Nucl Med Biol. 2009;36(4):395–402. doi: 10.1016/j.nucmedbio.2009.01.001. - DOI - PubMed
    1. American Type Culture Collection. CAPAN-1—HTB-79. Manassas: American Type Culture Collection; 2022. [cited 2022 September 8]. Available from: https://www.atcc.org/products/htb-79.
    1. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) Surgery. 2014;155(6):977–988. doi: 10.1016/j.surg.2014.02.001. - DOI - PubMed
    1. Chen W, Zhang Z, Zhang S, Zhu P, Ko JK-S, Yung KK-L. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021;22(12):6567. doi: 10.3390/ijms22126567. - DOI - PMC - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. NEJM. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923. - DOI - PubMed

LinkOut - more resources